![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
ET Piros, PL Prather, HH Loh, PY Law, CJ Evans and TG Hales
Department of Psychiatry and Biobehavioral Sciences, University of California, School of Medicine, Los Angeles 90024, USA.
Members of the three classes of opioid receptors (mu, delta, and kappa) have been cloned and characterized in unexcitable cell lines using biochemical techniques. However, an important function of these cloned receptors, their coupling to voltage-activated Ca2+ channels, remains untested. We stably transfected cloned rat mu-opioid receptor cDNAs into clonal pituitary GH3 cells. GH3 cells expressing mu-opioid receptors (GH3MOR cells) bound the receptor-specific ligands [D-Ala2,Me- Phe4,Gly-ol5]-enkephalin (DAMGO) and morphine with high affinity (Ki = 1.0 and 7.2 nM, respectively), and these ligands also potently inhibited adenylyl cyclase activity (IC50 = 21.9 and 55.2 nM, respectively). Functional coupling of mu-opioid receptors to voltage- activated Ca2+ channels was compared with that of endogenous somatostatin (SRIF) receptors in GH3MOR cells, using the patch-clamp technique, with Ba2+ as the charge carrier. DAMGO (1 microM) and SRIF (1 microM) inhibited Ba2+ currents by 23.8 +/- 1.0% and 22.9 +/- 2.5%, respectively. DAMGO (0.1 nM to 10 microM) dose-dependently inhibited Ba2+ currents, with an IC50 of 105 nM. The mu-opioid receptor agonist morphine (1 microM) inhibited currents by 13.5 +/- 1.1% and the delta- opioid receptor-selective ligand [D-Pen2,5]-enkephalin (1 microM) caused only 3.5 +/- 2.1% inhibition. The inhibitory actions of DAMGO, morphine, and [D-Pen2,5]-enkephalin were reversed by naloxone. Ba2+ current inhibitions by DAMGO and SRIF were attenuated by pertussis toxin pretreatment. Nimodipine reduced the amplitude of Ba2+ current inhibition by DAMGO, suggesting that mu-opioid receptors couple to L- type Ca2+ channels in GH3MOR cells.
This article has been cited by other articles:
|
|
 |
|
  A. M. Lopez-Dominguez, J. L. Espinosa, A. Navarrete, G. Avila, and G. Cota Nerve growth factor affects Ca2+ currents via the p75 receptor to enhance prolactin mRNA levels in GH3 rat pituitary cells J. Physiol., July 15, 2006; 574(2): 349 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-Q. Wu, M. Li, J. Chen, Z.-Q. Chi, and J.-G. Liu Involvement of cAMP/cAMP-Dependent Protein Kinase Signaling Pathway in Regulation of Na+,K+-ATPase upon Activation of Opioid Receptors by Morphine Mol. Pharmacol., March 1, 2006; 69(3): 866 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zhang and J. J. Oppenheim Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems J. Leukoc. Biol., December 1, 2005; 78(6): 1210 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Claude-Geppert, J. Liu, J. Solberg, L. J. Erickson-Herbrandson, H. H. Loh, and P.-Y. Law Antagonist Efficacy in MORS196L Mutant Is Affected by the Interaction between Transmembrane Domains of the Opioid Receptor J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 216 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zhang, T. J. Rogers, M. Caterina, and J. J. Oppenheim Proinflammatory Chemokines, Such as C-C Chemokine Ligand 3, Desensitize {micro}-Opioid Receptors on Dorsal Root Ganglia Neurons J. Immunol., July 1, 2004; 173(1): 594 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Charles, N. Mostovskaya, K. Asas, C. J. Evans, M. L. Dankovich, and T. G. Hales Coexpression of delta -Opioid Receptors with {micro} Receptors in GH3 Cells Changes the Functional Response to {micro} Agonists from Inhibitory to Excitatory Mol. Pharmacol., January 1, 2003; 63(1): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Wallace Treatment options for refractory pain: The role of intrathecal therapy Neurology, September 10, 2002; 59(90052): S18 - 24. [Abstract] [Full Text]
|
|
|
|
|
|
J.-G. Liu and P. L. Prather Chronic Agonist Treatment Converts Antagonists into Inverse Agonists at delta -Opioid Receptors J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1070 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Safa, J. Boulter, and T. G. Hales Functional Properties of CaV1.3 (alpha 1D) L-type Ca2+ Channel Splice Variants Expressed by Rat Brain and Neuroendocrine GH3 Cells J. Biol. Chem., October 12, 2001; 276(42): 38727 - 38737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Martin, M. T. Terruso, and P. L. Prather Agonist Activity of the delta -Antagonists TIPP and TIPP-psi in Cellular Models Expressing Endogenous or Transfected delta -Opioid Receptors J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 240 - 248. [Abstract] [Full Text]
|
|
|
|
|
|
J.-G. Liu and P. L. Prather Chronic Exposure to {micro}-Opioid Agonists Produces Constitutive Activation of {micro}-Opioid Receptors in Direct Proportion to the Efficacy of the Agonist Used for Pretreatment Mol. Pharmacol., July 1, 2001; 60(1): 53 - 62. [Abstract] [Full Text]
|
|
|
|
|
|
N. A. Martin and P. L. Prather Interaction of Co-Expressed {micro}- and {delta}-Opioid Receptors in Transfected Rat Pituitary GH3 Cells Mol. Pharmacol., April 1, 2001; 59(4): 774 - 783. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. T. Williams, M. J. Christie, and O. Manzoni Cellular and Synaptic Adaptations Mediating Opioid Dependence Physiol Rev, January 1, 2001; 81(1): 299 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Prather, L. Song, E. T. Piros, P. Y. Law, and T. G. Hales delta -Opioid Receptors Are More Efficiently Coupled to Adenylyl Cyclase Than to L-Type Ca2+ Channels in Transfected Rat Pituitary Cells J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 552 - 562. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. T. Piros, R. C. Charles, L. Song, C. J. Evans, and T. G. Hales Cloned delta -Opioid Receptors in GH3 Cells Inhibit Spontaneous Ca2+ Oscillations and Prolactin Release Through KIR Channel Activation J Neurophysiol, May 1, 2000; 83(5): 2691 - 2698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Friedrich and G. F. Gebhart Effects of Spinal Cholecystokinin Receptor Antagonists on Morphine Antinociception in a Model of Visceral Pain in the Rat J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 538 - 544. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Filizola, L. Laakkonen, and G. H. loew 3D modeling, ligand binding and activation studies of the cloned mouse {delta}, {micro} and {kappa} opioid receptors Protein Eng. Des. Sel., November 1, 1999; 12(11): 927 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Law and H. H. Loh Regulation of Opioid Receptor Activities J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 607 - 624. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. Charles, E. T. Piros, C. J. Evans, and T. G. Hales L-type Ca2+ Channels and K+ Channels Specifically Modulate the Frequency and Amplitude of Spontaneous Ca2+ Oscillations and Have Distinct Roles in Prolactin Release in GH3 Cells J. Biol. Chem., March 12, 1999; 274(11): 7508 - 7515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Law, T. M. McGinn, K. M. Campbell, L. E. Erickson, and H.H. Loh Agonist Activation of delta -Opioid Receptor but not {micro}-Opioid Receptor Potentiates Fetal Calf Serum or Tyrosine Kinase Receptor-Mediated Cell Proliferation in a CellLine-Specific Manner Mol. Pharmacol., January 1, 1997; 51(1): 152 - 160. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Knoflach, R. K. Reinscheid, O. Civelli, and J. A. Kemp Modulation of Voltage-Gated Calcium Channels by Orphanin FQ in Freshly Dissociated Hippocampal Neurons J. Neurosci., November 1, 1996; 16(21): 6657 - 6664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Liu, M. B. Ruckle, and P. L. Prather Constitutively Active {micro}-Opioid Receptors Inhibit Adenylyl Cyclase Activity in Intact Cells and Activate G-proteins Differently than the Agonist [D-Ala2,N-MePhe4,Gly-ol5]Enkephalin J. Biol. Chem., October 5, 2001; 276(41): 37779 - 37786. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
